Psoriasis is a complex, chronic relapsing and inflammatory skin disorder with a prevalence
of approximately 2% in the general population worldwide. Psoriasis can be triggered by …

Progress in understanding of the mechanisms underlying chronic inflammatory skin
disorders, such as atopic dermatitis and psoriasis vulgaris, has led to new treatment options …

Psoriasis is a common inflammatory disease of especially high recurrence rate (90%) which
is suffered by approximately 3% of the world population. The overexpression of reactive …

An estimated 20–25% of the population is affected by chronic, non-communicable
inflammatory skin diseases. Chronic skin inflammation has many causes. Among the most …

Obesity is a major public health issue worldwide since it is associated with the development
of chronic comorbidities such as type 2 diabetes, dyslipidemias, atherosclerosis, some …

Psoriasis is a common, chronic, and inflammatory skin disease with a high burden on
individuals, health systems, and society worldwide. With the immunological pathologies and …

Existing therapeutics for autoimmune diseases remain problematic due to low efficacy,
severe side effects, and difficulties to reach target tissues. Herein, we design multifunctional …

Psoriasis is an immune-mediated disease with a strong genetic component that brings many
challenges to sick individuals, such as chronic illness, and which has multiple associated …

Risankizumab is a humanized IgG monoclonal antibody inhibitor of IL23 and has been
recently approved by the EMA and the FDA for the treatment of moderate to severe plaque …

The IL-17 family of cytokines and receptors have central roles in host defence against
infection and development of inflammatory diseases. The compositions and structures of …